La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Onconetix a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Onconetix..

Onconetix (NASDAQ:ONCO) Azioni, Catena delle Opzioni

Onconetix

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Onconetix Inc

ONCO-INNOVATIONS LTD by ONCO-INNOVATIONS LTD.

OncoCyte Corp

ONCOSEC MEDICAL INC NEW by OncoSec Medical Incorporated

OncoSec Medical Inc

OncoSil Medical Ltd

ONCOVISTA INNVTVE THERPS by OncoVista Innovative Therapies, Inc.

OncoVista Innovative Therapies Inc

ONCOLOGIX TECH INC by Oncologix Tech, Inc.

Oncologix Tech Inc

ONCOLOGY PHARMA INC by Oncology Pharma Inc.

Oncology Pharma Inc

Oncolytics Biotech Inc

Oncopeptides AB

Oncorus Inc rdinary Shares

ONCOTELIC THERAPEUTCS INC by Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc

Press Releases

Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds

Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds

Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders

Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing

Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress

Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort

Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.

ENTO

ONCO

VRNA

Apollomics

Aptevo Therapeutics

Bone Biologics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Entero Therapeutics

GRI Bio

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Scorpius Holdings

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Tharimmune

Vincerx Pharma

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

ZyVersa Therapeutics, Inc. - Common Stock

Comments

Onconetix

Onconetix (ONCO) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO